[reaction: see text] The Diels-Alder reactions of masked o-benzoquinones (MOBs) with [60]fullerene, affording novel and highly functionalized bicyclo[2.2. 2]octenone-fused [60]fullerene derivatives, are described.
Syntheses of (±)-cis-3-hydroxycarbonyl-7-(phenylacetamido)carbacephem (10 ), (±)-cis-3-methoxycarbonyl-7-(phenylacetamido)carbacephem (11 ), (±)-cis-2-chloro-3-hydroxycarbonyl-7-(phenylacetamido)carbacephem (14 ), and (±)-cis-2-chloro-3-methoxycarbonyl-7-(phenylacetamido)carbacephem (15 ) were accomplished. These four heretofore undescribed compounds 10 , 11 , 14 , and 15 showed notable activity against Staphylococcus aureus FDA 209P, Escherichia coli ATCC 39188, Pseudomonas aeruginosa 1101-75, Klebsiella pneumoniae NCTC 418 as well as the β-lactamase producing organisms E. coli A9675, P. aeruginosa 18S-H and methicillin-resistant organism S. aureus 95. The electronic activation of lactam moieties of 11 and 15 enhanced remarkably their antibacterial activity relative to those of the 10 and 14 . The chlorine atom in 14 and 15 , acting as an effective leaving group, also resulted in an increment in the biological activity in comparison with those of the parent carbacephemes 10 and 11 . The mode of action related to 14 and 15 can be explained by a non-classical [1,4]-elimination process.
3542
Poster Board III-479
Background
The interaction between SDF-1 and its receptor, CXCR4, is responsible for retaining of stem cells in the bone marrow. CXCR4 antagonist disrupts the SDF-1/CXCR4 interaction and mobilizes CD34+ hematopoietic stem cells (CD34+ HSCs) and CD133+ endothelial progenitor cells (CD133+ EPCs) from bone marrow into circulation, which can be used as a source for stem cell transplantation and other potential clinical indications. TG-0054 is a novel CXCR4 antagonist. In vitro CXCR4 antagonistic activity and in vivo stem cell mobilization activity of TG-0054 were determined in this study.
Materials and Methods
In vitro pharmacological assays, including GTP-binding assay, calcium mobilization assay, and chemotaxis assays, were performed to assess the potency of TG-0054 as a CXCR4 antagonist. In addition, receptor-binding assays against a panel of human chemokine receptors as well as other 68 cellular receptors were screened to evaluate the specificity of TG-0054. Kinetics and dose-dependent response of stem cell mobilization by TG-0054 were demonstrated in BALB/c mice. Activity of stem cell mobilization of TG-0054 when used alone or combined with G-CSF was also studied.
Results
TG-0054 blocked SDF-1-binding to CXCR4 receptor with an IC50 of 10 nM and inhibited SDF-1–induced GTP-binding (IC50 = 6 nM), chemotaxis (IC50 = 43 nM), and calcium mobilization (IC50 = 59 nM). TG-0054 showed greater than 3000-fold selectivity for CXCR4 receptor over other chemokine receptors. It is noteworthy that the IC50 for the inhibitory effect of TG-0054 on hERG potassium currents was greater than 1000 μM when human embryonic kidney (HEK) cells were used to examine the in vitro effects on the hERG potassium channel currents. In animal studies, TG-0054 rapidly and effectively mobilized CD34+ HSCs and CD133+ EPCs into circulation. Single intravenous (IV) administration of TG-0054 resulted in a rapid increase of total white blood cell (WBC) counts, as well as CXCR4+, CD34+, and CD133+ cells in peripheral blood between 1–3 hour post-injection and the cell counts returned to baseline within 6 hours. At their maximum tolerated doses (MTD), TG-0054 increased CXCR4+ cells by 28.7-fold in mice. Furthermore, TG-0054 efficiently mobilized CD34+ (14.5-fold) and CD133+ (7.9-fold) cells. The combined effects of TG-0054 and G-CSF on HSCs and EPCs mobilization from the bone marrow in mice were also investigated. G-CSF (100 μg/kg/day) was administered subcutaneously (SC) from Day 1 to Day 4 followed by a single IV injection of TG-0054 or AMD3100 on Day 5. Synergistic effects were observed in all cell types in mice receiving combination of G-CSF and 50 mg/kg of TG-0054 (total WBC 23.0-fold, CXCR4+ 29.0-fold, CD34+ 37.1-fold, CD133+ 110.8-fold of increase in combination group).
Conclusion
It was concluded that TG-0054 was a potent and selective CXCR4 antagonist intended for the use of stem cell transplant and other clinical indications. It showed strong stem cell mobilization activity comparable to G-CSF when used alone, and demonstrated synergistic effects when combined with G-CSF in a nonclinical model.
Disclosures:
Huang: TaiGen Biotechnology Inc.: Employment. Liu:TaiGen Biotechnology Inc.: Employment. Yen:TaiGen Biotechnology Inc.: Employment. Chen:TaiGen Biotechnology Inc.: Consultancy. Chen:TaiGen Biotechnology Inc.: Consultancy. King:TaiGen Biotechnology Inc.: Employment. Hsu:TaiGen Biotechnology, Inc.: Membership on an entity's Board of Directors or advisory committees.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.